(Total Views: 165)
Posted On: 01/03/2022 2:39:52 PM
Post# of 44044
$SPRC SciSparc is a clinical-stage biotechnology company developing cannabinoid-based therapeutics. The company's lead asset, SCI-110
(synthetic THC + palmitoylethanolamide (PEA)), is being developed for Tourette
syndrome (TS) (phase 2b) and Alzheimer's disease (AD) and agitation (phase 2a).
Additionally, SciSparc is developing SCI–210 (CBD + PEA) for status epilepticus
and autism spectrum disorder, and SCI-160 (a synthetic CB2 receptor agonist)
for pain. The company's achievements in 2021 included preparing to enter midstage studies with SCI-110, publishing key data underpinning the efficacy of its
programs, garnering additional IP protection, bolstering the balance sheet with
successful capital markets activities, and uplisting to the Nasdaq exchange.
(synthetic THC + palmitoylethanolamide (PEA)), is being developed for Tourette
syndrome (TS) (phase 2b) and Alzheimer's disease (AD) and agitation (phase 2a).
Additionally, SciSparc is developing SCI–210 (CBD + PEA) for status epilepticus
and autism spectrum disorder, and SCI-160 (a synthetic CB2 receptor agonist)
for pain. The company's achievements in 2021 included preparing to enter midstage studies with SCI-110, publishing key data underpinning the efficacy of its
programs, garnering additional IP protection, bolstering the balance sheet with
successful capital markets activities, and uplisting to the Nasdaq exchange.
(0)
(0)
